11/14
04:18 pm
abus
Arbutus Biopharma (NASDAQ:ABUS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $5.00 price target on the stock.
Low
Report
Arbutus Biopharma (NASDAQ:ABUS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $5.00 price target on the stock.
11/13
08:07 am
abus
Arbutus Biopharma GAAP EPS of -$0.04 misses by $0.01, revenue of $0.53M misses by $0.42M [Seeking Alpha]
Medium
Report
Arbutus Biopharma GAAP EPS of -$0.04 misses by $0.01, revenue of $0.53M misses by $0.42M [Seeking Alpha]
11/13
07:30 am
abus
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Medium
Report
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
10/7
08:07 am
abus
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025 [Yahoo! Finance]
Low
Report
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025 [Yahoo! Finance]
10/7
08:00 am
abus
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
Low
Report
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
10/3
03:30 pm
abus
Arbutus Biopharma (NASDAQ:ABUS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Arbutus Biopharma (NASDAQ:ABUS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.